Alnylam Pharmaceuticals (ALNY)

Alnylam Pharma (ALNY) Stock Price & Analysis


ALNY Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$122.57 - $242.97
Previous Close$192.3
Average Volume (3M)741.71K
Market Cap
Enterprise Value$23.20B
Total Cash (Recent Filing)$2.07B
Total Debt (Recent Filing)$1.32B
Price to Earnings (P/E)-22.1
Aug 01, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.70
Shares Outstanding124,525,737
10 Day Avg. Volume511,538
30 Day Avg. Volume741,710
Standard Deviation0.13
Financial Highlights & Ratios
Price to Book (P/B)-87.19
Price to Sales (P/S)75.00
Price to Cash Flow (P/CF)-34.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue16.48
Enterprise Value/Gross Profit13.10
Enterprise Value/Ebitda-38.86
Price Target Upside32.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $122.57 and its highest was $242.97 in the past 12 months.
    What is Alnylam Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Alnylam Pharmaceuticals’s upcoming earnings report date?
    Alnylam Pharmaceuticals’s upcoming earnings report date is Aug 01, 2023 which is in 55 days.
      How were Alnylam Pharmaceuticals’s earnings last quarter?
      Alnylam Pharmaceuticals released its earnings results on May 04, 2023. The company reported -$1.4 earnings per share for the quarter, beating the consensus estimate of -$1.67 by $0.27.
        Is Alnylam Pharmaceuticals overvalued?
        According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Alnylam Pharmaceuticals pay dividends?
          Alnylam Pharmaceuticals does not currently pay dividends.
          What is Alnylam Pharmaceuticals’s EPS estimate?
          Alnylam Pharmaceuticals’s EPS estimate is -$1.51.
            How many shares outstanding does Alnylam Pharmaceuticals have?
            Alnylam Pharmaceuticals has 124,525,734 shares outstanding.
              What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
              Alnylam Pharmaceuticals reported an EPS of -$1.4 in its last earnings report, beating expectations of -$1.67. Following the earnings report the stock price went up 2.952%.
                Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
                Among the largest hedge funds holding Alnylam Pharmaceuticals’s share is Dodge & Cox. It holds Alnylam Pharmaceuticals’s shares valued at 780M.


                  Alnylam Pharma Stock Smart Score

                  The Alnylam Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Alnylam Pharmaceuticals

                  Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.


                  Top 5 ETFs holding ALNY

                  Market Value
                  Smart Score
                  Vanguard Growth ETF
                  Vanguard Health Care ETF
                  iShares Russell 1000 Growth ETF
                  Vanguard Large-Cap ETF
                  Capital Group Growth ETF
                  Up to five ETFs with an Outperform Smart Score that hold ALNY. The ETFs are listed according to market value of ALNY within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Arrowhead Pharmaceuticals
                  Sarepta Therapeutics
                  Editas Medicine

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis